ARVN Arvinas Inc

By Chris Wack

Arvinas Inc. and Pfizer Inc. said they entered into a global collaboration to develop and commercialize ARV-471, an investigational oral Proteolysis Targeting Chimera estrogen receptor protein degrader, a well-known disease driver in most breast cancers.

The companies said ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.

Under the terms of the agreement, Pfizer will pay Arvinas $650 million upfront. Pfizer will also make a $350 million equity investment in Arvinas.

The companies will equally share worldwide development costs, commercialization expenses, and profits.

ARV-471 currently is being evaluated as a treatment for metastatic breast cancer in a Phase 1 dose escalation study, a Phase 1b combination study with Pfizer's Ibrance palbociclib, and a Phase 2 monotherapy dose expansion study. Arvinas and Pfizer expect to initiate two additional trials of ARV-471 in 2021, including a second Phase 1b combination trial with everolimus and a trial in the neoadjuvant setting.

Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones, in addition to sharing profits on ARV-471 worldwide.

Arvinas shares rose 6% to $82 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 22, 2021 07:50 ET (11:50 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.